Results 61 to 70 of about 596 (129)

Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) did not improve total pathological complete response (tpCR) rates or breast pathological complete response (bpCR) rates compared with dual blockade with trastuzumab and pertuzumab (TP), but was associated with greater grade ≥ 3 toxicity, particularly diarrhea.
Jiahui Huang   +17 more
wiley   +1 more source

Interstitial Fibrosis as a Common Counterpart of Histopathological Risk Factors in Papillary Thyroid Microcarcinoma: A Retrospective Analysis

open access: yesDiagnostics
Purpose. Interstitial fibrosis in papillary thyroid microcarcinoma is a subject which is under-investigated. The aim of this study is to determine the relationship between interstitial fibrosis, the subtypes of papillary microcarcinoma, and the ...
Can Sahin   +5 more
doaj   +1 more source

Evaluation and Management of Thyroid Nodules: A Joint Consensus Statement From the British Thyroid Association (BTA), British Association of Endocrine and Thyroid Surgeons (BAETS) and Collaborating Bodies

open access: yes
Clinical Endocrinology, Volume 104, Issue 6, Page 682-692, June 2026.
Ram Moorthy   +10 more
wiley   +1 more source

Long‐Term Outcomes of Radiofrequency Ablation for Benign Thyroid Nodules of Different Sizes: Implications of Regrowth and New Growth

open access: yesThe Kaohsiung Journal of Medical Sciences, Volume 42, Issue 1, January 2026.
ABSTRACT Radiofrequency ablation is an effective treatment for benign thyroid nodules. Since initial nodule volume may impact the efficacy of radiofrequency ablation, this study evaluated its long‐term outcomes across varying nodule sizes, focusing on regrowth, new growth, and clinical management implications.
Chia‐Yin Lu   +10 more
wiley   +1 more source

Fibrillary Glomerulonephritis Associated with Thyroid Papillary Microcarcinoma: A Case Report

open access: yesTurkish Journal of Nephrology, 2019
In this report, we describe a case of fibrillary glomerulonephritis associated with thyroid papillary microcarcinoma arising in a 54-year-old female patient suffering from Hashimoto’s thyroiditis.
Gülay ULUSAL OKYAY   +6 more
doaj  

A new paradigm in low-risk papillary microcarcinoma: active surveillance

open access: yesEndocrinology, Diabetes & Metabolism Case Reports, 2017
Classical papillary thyroid microcarcinoma (PTMC) is a variant of papillary thyroid carcinoma (PTC) known to have excellent prognosis. It has a mortality of 0.3%, even in the presence of distance metastasis.
Alex González Bóssolo   +5 more
doaj   +1 more source

Malignancy Risk, Molecular Mutations, and Surgical Outcomes of Thyroid Nodules Classified as Atypia of Undetermined Significance in the Bethesda System: A Comprehensive Analysis

open access: yesCytopathology, Volume 37, Issue 1, Page 66-75, January 2026.
This study investigates the correlation between AUS subcategories, molecular mutations, and surgical outcomes in thyroid nodules classified as atypia of undetermined significance (AUS) under the Bethesda System for Reporting Thyroid Cytopathology.
Caroline Bourque   +7 more
wiley   +1 more source

Thyrotoxicosis due to Hashimoto's disease triggered by radiofrequency ablation for low-risk papillary thyroid microcarcinoma: A case report

open access: yesRadiology Case Reports
This paper reports a case of acute thyrotoxicosis (Hashitoxicosis) in a 48-year-old woman following RFA for a low-risk papillary thyroid microcarcinoma.
Van Bang Nguyen   +3 more
doaj   +1 more source

Medullary thyroid carcinoma and RET molecular testing: A virtual tumor board on clinical decision‐making

open access: yes
CA: A Cancer Journal for Clinicians, Volume 76, Issue 3, May/June 2026.
Lucas Kallas‐Silva   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy